| . pH-dependent regulation of camptothecin induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine M Sorensen, M Sehested, PB Jensen Biochem. Pharmacol 54, 373-380, 1997 | 26 | 1997 |
| 11.3 Treatment of SCLC: chemotherapy HH Hansen, M Sørensen Textbook of Lung Cancer, 184, 2008 | | 2008 |
| 117 Characterization of high and low level resistance to topoisomerase I poisons in small cell lung cancer cells resistant to camptothecin and topotecan M Sorensen, M Sehested, IJ Christensen, PB Jensen Lung Cancer, 33, 1997 | 1 | 1997 |
| 29 A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors U Lassen, JHM Schellens, LL Siu, DJ Jonker, M Sorensen, T Jarutat, ... European Journal of Cancer, 12, 2012 | 7 | 2012 |
| 357 POSTER A phase I safety, pharmacokinetic and pharmacodynamic study of intravenously administered PXD101 plus carboplatin or paclitaxel or both in patients with advanced … U Lassen, M Sørensen, JS De Bono, R Molife, L Vidal, S Settatree, ... EJC Supplements 12 (4), 111, 2006 | | 2006 |
| 419 POSTER A phase I safety and pharmacokinetic (PK) study of 3 and 6 hours (h) intravenously administered belinostat (PXD101) plus carboplatin (C) and paclitaxel (P) in … M Sorensen, J Tjørnelund, PB Jensen Ejc Supplements 12 (6), 132, 2008 | | 2008 |
| 505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine J Tabernero, K Homicsko, JH Schellens, O Hoekstra, L Van der Veen, ... European Journal of Cancer 3 (51), S104-S105, 2015 | 2 | 2015 |
| 591P Distress and perceived information among patients in phase I trials and their relatives: A prospective study KT Gad, SO Dalton, PB Envold, AK Duun-Henriksen, UN Lassen, ... Annals of Oncology 31, S497, 2020 | | 2020 |
| 6105 POSTER Phase II Trial of Temsirolimus Alone and in Combination With Irinotecan for KRas Mutant Chemotherapy Resistant Metastatic Colorectal Cancer and the Importance of … KG Spindler, M Sorensen, N Pallisgaard, RF Andersen, U Lassen, ... European Journal of Cancer, S423, 2011 | | 2011 |
| 696 Immunohistochemical detection of topoisomerase II α (Topollα) P-glycoprotein (Pgp), and multidrug resistance protein (MRP) in non small cell lung cancer (NSCLC) and in … J Kreisholt, M Sørensen, PB Jensen, BS Nielsen, CB Andersen, ... Lung Cancer, 178, 1997 | | 1997 |
| A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small cell lung cancer M Sorensen, PB Jensen, J Herrstedt, FR Hirsch, HH Hansen annals of oncology 11, 829-835, 2000 | 35 | 2000 |
| A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. M Mau-Soerensen, ARA Razak, AF Shields, NY Gabrail, JF Gerecitano, ... Journal of Clinical Oncology 32 (15_suppl), 2537-2537, 2014 | 8 | 2014 |
| A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors A Awada, FALM Eskens, DG Robbrecht, UN Lassen, M Sorensen, ... Annals of Oncology 29, viii418, 2018 | | 2018 |
| A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 … D Meulendijks, MPJK Lolkema, EE Voest, MJ De Jonge, S Sleijfer, ... Journal of Clinical Oncology 31 (15_suppl), 2522-2522, 2013 | 12 | 2013 |
| A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours MTJ van Bussel, A Awada, MJA de Jonge, M Mau-Sørensen, D Nielsen, ... British Journal of Cancer 124 (4), 728-735, 2021 | 88 | 2021 |
| A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors. M van Bussel, M Mau-Soerensen, L Damstrup, D Nielsen, HMW Verheul, ... Journal of Clinical Oncology 35 (15_suppl), 2556-2556, 2017 | 9 | 2017 |
| A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia R Garzon, M Savona, R Baz, M Andreeff, N Gabrail, M Gutierrez, L Savoie, ... Blood, The Journal of the American Society of Hematology 129 (24), 3165-3174, 2017 | 154 | 2017 |
| A phase 1 dose escalation study of the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML) R Garzon, I Flinn, J Berdeja, KWL Yee, M Savona, M Kauffman Haematologica 99 (s1), 527, 2014 | 3 | 2014 |
| A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL) M Gutierrez, A Goy, JC Byrd, JM Flynn, M Sorensen, P Brown, NY Gabrail, ... J Clin Oncol 32 (15s), 8518, 2014 | 15 | 2014 |
| A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia … KWL Yee, M Savona, M Sorensen, P Brown, WG Blum, DJ DeAngelo, ... Journal of Clinical Oncology 32 (15_suppl), 7032-7032, 2014 | 9 | 2014 |
Ulrik Lassen, Professor, MD, PH.D.Phase 1 Unit, Department of OncologyVerified email at regionh.dk
